Extended Access of Momelotinib in Adults With Myelofibrosis (NCT03441113)
Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT01969838), GS-US-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746), SRA-MMB-301 who are currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg and 200 mg tablets) and have not experienced progression of disease. The secondary objective is to assess overall survival (OS) and leukemia free survival (LFS) in all subjects.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (112 Sites)
Showing the first 25 of 112 sites.
- GSK Investigational Site — Scottsdale, Arizona
- GSK Investigational Site — Orange, California
- GSK Investigational Site — Stanford, California
- GSK Investigational Site — Aurora, Colorado
- GSK Investigational Site — Jacksonville, Florida
- GSK Investigational Site — Tampa, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Baltimore, Maryland
- GSK Investigational Site — Boston, Massachusetts
- GSK Investigational Site — Rochester, Minnesota
- GSK Investigational Site — St Louis, Missouri
- GSK Investigational Site — Hackensack, New Jersey
- GSK Investigational Site — The Bronx, New York
- GSK Investigational Site — Cleveland, Ohio
- GSK Investigational Site — South Brisbane, Queensland
- GSK Investigational Site — Bedford Park, South Australia
- GSK Investigational Site — Frankston, Victoria
- GSK Investigational Site — Melbourne, Victoria
- GSK Investigational Site — Melbourne, Victoria
- GSK Investigational Site — Perth, Western Australia
- GSK Investigational Site — Linz,
- GSK Investigational Site — Vienna,
- GSK Investigational Site — Antwerp,
- GSK Investigational Site — Bruges,
- GSK Investigational Site — Leuven,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasms
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers — St Louis, Missouri
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) — Goodyear, Arizona
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors — Birmingham, Alabama
- Hispanic Adapted and Culturally Relevant Exercising Together — Tucson, Arizona
- M7824 Related Adverse Effects in Adults With Cancer — Bethesda, Maryland
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors — Duarte, California
Explore by condition: All Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.